This medication conflict checker helps families of children with congenital hyperinsulinism (HI) find out whether current treatments could affect clinical trial eligibility. Select one or more medications below to screen active HI trials for potential conflicts.
Most HI trials are add-on studies: the child stays on diazoxide, octreotide or feeds and the study drug is added on top, so a current medicine is more often a requirement than a barrier. Trials usually ask for a stable dose for a set number of weeks before enrollment, and imaging studies of 18F-DOPA PET have their own rules about recent surgery and sedation. Each trial publishes its own criteria, and they differ.
Diazoxide
Proglycem, generic diazoxide oral suspension — the first-line HI medicine and the usual backbone of standard of care in add-on trials. Studies more often require a stable diazoxide dose for several weeks than exclude it. Some trials enroll only diazoxide-unresponsive children, so a documented response or non-response can decide eligibility either way.
Somatostatin Analogs
octreotide (Sandostatin), octreotide LAR, lanreotide (Somatuline Depot) — allowed as background therapy in most add-on trials if the dose has been stable, since these are standard second-line HI treatments. Trials of new glucagon-type drugs may ask about octreotide because both change liver glucose output. Long-acting monthly shots may need to be timed around study visits.
Glucagon and Dextrose
glucagon rescue kits, IV dextrose, continuous tube feeds of dextrose or maltodextrin — rescue glucagon is almost always permitted and often required as an emergency plan. Trials of glucagon analogs (dasiglucagon, efpegerglucagon) count rescue glucagon use as an outcome rather than a conflict. Children who depend on IV dextrose are usually studied in hospital-based trials with their own rules.
Diuretics and Other Supportive Medicines
chlorothiazide, hydrochlorothiazide, anti-seizure medicines, reflux medicines — the water pill prescribed with diazoxide is rarely an issue. Anti-seizure medicines are usually allowed if the dose is stable; a few trials exclude children with uncontrolled seizures rather than the drugs themselves. Phenytoin can lose effect when combined with diazoxide, which is a prescribing issue, not a trial issue.
Drugs the 2024 guideline advises against may be flagged
The international HI guideline says sirolimus should not be used outside an approved study and that glucocorticoids are not effective and should be avoided. Trials often exclude both, and sirolimus usually needs a washout. If your child takes either, the checker may flag it at low confidence; the study team will want to know why it was started.
A conflict often means a timing rule, not a no
HI trials typically require a stable dose of diazoxide or octreotide for a set period before the first study dose, and surgery or 18F-DOPA PET studies may require a gap after a recent pancreatectomy. The checker shows the trial's own wording so you can see whether it is a washout, a stability window or a true exclusion.
After a pancreatectomy
Children who still have lows after a near-total pancreatectomy were specifically included in the dasiglucagon and ersodetug trials, and children who developed diabetes after surgery are sometimes eligible for different studies. Insulin or pancreatic enzyme replacement started after surgery is usually allowed; tell the study team about every post-surgical medicine.
Don't see your child's medication listed?
The checker covers the medicines most relevant to HI families: diazoxide, somatostatin analogs, glucagon, diuretics, anti-seizure drugs and common supportive medicines. If a medicine is not in the list, it has not come up often in HI trial exclusion criteria. Always tell the study team about everything your child takes, including feeds and supplements.
How the medication conflict checker works: This free tool helps HI families learn whether current medications could affect clinical trial eligibility. It scans the published eligibility criteria of every active congenital hyperinsulinism trial and flags those that may exclude a specific treatment. Matches are grouped by confidence: high confidence means the trial names the exact drug, medium means it references the drug class, and low means it uses broad language that may or may not apply. Always confirm eligibility with the study team, since final decisions depend on the child's gene result, diazoxide response, surgical history and the HI center's assessment.
Across 1,853 open rare disease treatment trials, a third exclude people over a medication they commonly take. See which medications and diseases, in our September 2026 analysis.
Sources: International Guidelines for the Diagnosis and Management of Hyperinsulinism (Horm Res Paediatr, 2024); Proglycem prescribing information (Rev. 10/2026); ClinicalTrials.gov records NCT06208215, NCT03941236, NCT04732416, NCT05088798, NCT04205604, NCT02021604.